62
Participants
Start Date
February 29, 2008
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2
Ixabepilone, 40 mg/m\^2, administered as a 3-hour intravenous (IV) infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2
Ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2
Docetaxel 75 mg/m\^2 administered as a 1-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
Hematology Oncology Associates of Rockland, Nyack
Arena Oncology Associates, PC, Lake Success
Hematology & Oncology Associates of Nepa, Dunmore
Doylestown Hospital, Doylestown
Regional Hematology Oncology, PC, Langhorne
St Mary Medical Center, Langhorne
Local Institution, Philadelphia
Albert Einstein Cancer Center, Philadelphia
Local Institution, Newark
Georgetown University Medical Center, Washington D.C.
Center for Cancer & Blood Disorders, PC, Bethesda
Sinai Hospital of Baltimore, Baltimore
Peninsula Cancer Institute, Newport News
Marion L Shepard Cancer Center, Washington
Gaston Hematology and Oncology, Gastonia
Santee Hematology/Oncology, Sumter
Charleston Cancer Center, Charleston
Lowcountry Hematology & Oncology, PA, Mt. Pleasant
Medical Oncology Associates of Augusta, PC, Augusta
Local Institution, Jacksonville
Local Institution, Miami
Dch Cancer Treatment Center, Tuscaloosa
Kingsport Hematology Oncology, Kingsport
The University of Tennessee Medical Center, Knoxville
Jackson Oncology Associates, Pllc, Jackson
University Medical Center, Inc, Louisville
University of Kentucky, Lexington
Mid Ohio Oncology/Hematology, Inc, dba The Mark H Zangmeister Center, Columbus
Akron General Medical Center, Akron
Summa Health System, Akron
Local Institution, Canton
Monroe Medical Associates, Munster
Center for Cancer Care at Goshen Health System, Goshen
Leah L Dietrich, MD, La Crosse
Sanford Cancer Center Oncology Clinic, Sioux Falls
Midwestern Regional Medical Center, Zion
Northwestern University Feinberg School of Medicine, Chicago
John W Kugler, MD, Peoria
Cancer Center of Kansas, Wichita
Hematology/Oncology Clinic, Baton Rouge
Mary Bird Perkins Cancer Center, Baton Rouge
Edward L Middleman, MD, Duncanville
Southlake Oncology, Southlake
Section Chief Medical Oncology, Houston
Cancer Specialists of South Texas, Corpus Christi
Coastal Bend Cancer Center, Corpus Christi
Austin Cancer Centers, Austin
Jose A Figueroa, MD, Lubbock
UNM Cancer Center, Albuquerque
New Mexico Cancer Care Associates (NMCCA), Santa Fe
Scripps Cancer Center, La Jolla
Local Institution, Honolulu
Providence Cancer Center, Spokane
Cancer Center of Central Connecticut, Southington
The Center for Cancer and Hematologic Disease, Cherry Hill
The Cancer Center at Hackensack University Medical Center, Hackensack
Howell Office Plaza, Howell Township
Local Institution, Newark
Cooper Hospital, Division of Hematology/Oncology, Voorhees Township
Local Institution, Woonsocket
Lead Sponsor
R-Pharm
INDUSTRY